Since collecting clinical data is difficult with Orphan diseases such as CF, a novel approach was used that relied on evidence from laboratory-based in vitro assay data where specified CFTR mutations showed gain of function at the single channel level and would likely translate to clinical benefit. Here, CFTR is linked to cystic fibrosis.